Astrocytoma, IDH-Mutant, Grade 3 — knowledge graph · CancerIndex

Knowledge graph · Cancer

Astrocytoma, IDH-Mutant, Grade 3

molecular subtype

Identifier: CI-CAN-00001840
Entity page: /cancer/astrocytoma-idh-mutant-grade-3 ↗
Edges: 12

Neighbours: 4 drugs8 trials
Drawn: 12 of 12 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Astrocytoma, IDH-Mutant, Grade 3 investigated in trials for …INVESTIGATED_IN_TRIALSderived4 of 4
→ investigated in trials for	Safusidenibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Astrocytoma, IDH-Mutant, Grade 3	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants

Astrocytoma, IDH-Mutant, Grade 3 studied in …STUDIED_INderived8 of 8
→ studied in	NCT03528642Phase 1 · active not recruiting Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma · condition mapped ONTOLOGY_EXACT · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 3	1	Observed	clinicaltrials	graph →
→ studied in	NCT07703436Phase 2 · not yet recruiting Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease · condition mapped ONTOLOGY_EXACT · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 3	1	Observed	clinicaltrials	graph →
→ studied in	NCT06860594Phase 1 · recruiting Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma · condition mapped CURATED_BROADER · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 3	1	Observed	clinicaltrials	graph →
→ studied in	NCT07215910Phase 3 · recruiting Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer · condition mapped ONTOLOGY_EXACT · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 3	1	Observed	clinicaltrials	graph →
→ studied in	NCT05303519Phase 3 · recruiting SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) · condition mapped ONTOLOGY_EXACT · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 3	1	Observed	clinicaltrials	graph →
→ studied in	NCT06815029Phase 1 · recruiting Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma · condition mapped CURATED_BROADER · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 3	1	Observed	clinicaltrials	graph →
→ studied in	NCT07673666completed GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3) · condition mapped ONTOLOGY_EXACT · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 3	1	Observed	clinicaltrials	graph →
→ studied in	NCT07468136Phase 1/Phase 2 · recruiting Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas · condition mapped ONTOLOGY_EXACT · 8 trials mapped (7 active)	—	—	Astrocytoma, IDH-Mutant, Grade 3	1	Observed	clinicaltrials	graph →